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The novel BH-3 mimetic apogossypolone induces
Beclin-1- and ROS-mediated autophagy in human
hepatocellular carcinoma cells
This article has been corrected since Online Publication and a corrigendum has also been published
P Cheng1,5, Z Ni1,5, X Dai2, B Wang1, W Ding1, A Rae Smith3, L Xu3, D Wu4, F He*,1 and J Lian*,1
Apogossypolone (ApoG2), a novel derivative of gossypol, exhibits superior antitumor activity in Bcl-2 transgenic mice, and
induces autophagy in several cancer cells. However, the detailed mechanisms are not well known. In the present study, we
showed that ApoG2 induced autophagy through Beclin-1- and reactive oxygen species (ROS)-dependent manners in human
hepatocellular carcinoma (HCC) cells. Incubating the HCC cell with ApoG2 abrogated the interaction of Beclin-1 and Bcl-2/xL,
stimulated ROS generation, increased phosphorylation of ERK and JNK, and HMGB1 translocation from the nucleus to
cytoplasm while suppressing mTOR. Moreover, inhibition of the ROS-mediated autophagy by antioxidant N-acetyl-cysteine
(NAC) potentiates ApoG2-induced apoptosis and cell killing. Our results show that ApoG2 induced protective autophagy in HCC
cells, partly due to ROS generation, suggesting that antioxidant may serve as a potential chemosensitizer to enhance cancer cell
death through blocking ApoG2-stimulated autophagy. Our novel insights may facilitate the rational design of clinical trials for
Bcl-2-targeted cancer therapy.
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Human hepatocellular carcinoma (HCC) is the third most
common malignancy and has a considerably high mortality
rate.1,2 Currently, treatment for patients with HCC mainly
consists of traditional chemotherapy, which often yields
unsatisfactory outcomes.3 Within this context, examination
of novel molecular target compounds is a priority. Among
these, inhibitors of the anti-apoptotic Bcl-2 family proteins
exhibited broad antitumor activity both in vitro and in vivo.4
The anti-apoptotic Bcl-2 family proteins consist of Bcl-2,
Bcl-xL, Mcl-1, A1 and Bcl-W, which are generally integrated
within the outer mitochondrial membrane.5 Overexpressed
and dysregulated, anti-apoptotic Bcl-2 proteins are seen in
various tumor types, such as prostate, non-Hodgkin’s
lymphoma, colorectal, breast, non-small cell lung cancer
and also HCC.6 Abundant evidence has shown that suppres-
sion of anti-apoptotic Bcl-2 proteins is a feasible strategy for
cancer therapy.7
Apogossypolone (ApoG2) is a novel gossypol derivative
designed by Ascenta Pharmaceuticals to reduce the toxicity
of gossypol (a natural pan-inhibitor of anti-apoptotic Bcl-2
family proteins). ApoG2 has been reported as a potent
inhibitor of Bcl-2, Bcl-xL, and Mcl-1.8 ApoG2 blocks the
interaction of Bim and Bcl-2, and induces apoptosis in a
number of human cancer cell lines.8–10 In addition, ApoG2
induces regression in several tumor xenograft models, and its
maximum tolerated dose appeared to be less toxic than
gossypol.10 Preclinical studies showed that ApoG2 had
significant anti-lymphoma and anti-pancreatic cancer
effects.9,11
Autophagy has recently become an important issue in
cancer research, and is emerging as a key regulator of
death pathways.12 It has been reported that ApoG2 induced
autophagy in several cancer cell lines such as breast, prostate
and lymphoma,13–15 but the mechanisms have not been
explored. In this study, we report that ApoG2 induces both
Beclin-1- and reactive oxygen species (ROS)-mediated
autophagy in HCC cells. Notably, we demonstrate that the
suppression of autophagy using antioxidants enhances cell
death induced by ApoG2, suggesting a new approach for
combinational therapy in treating HCC.
Results
ApoG2 induces autophagy in HCC cells. To test the
ability of ApoG2 to induce autophagy in HCC cells, we
analyzed LC-3 processing and localization, as well as
1Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China; 2Department of
Educational College, Chongqing Normal University, Chongqing, China; 3Departments of Molecular Biosciences and Radiation Oncology, University of Kansas Cancer
Center, University of Kansas, Lawrence, KS, USA and 4Key Laboratory of Biomedical Information Engineering of Education Ministry, School of Life Science and
Technology, Xi’an Jiaotong University, Xi’an, China
*Corresponding author: F He and J Lian, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, 30
Gaotanyan, Shapingba, Chongqing 400038, People’s Republic of China. Tel: þ 86 23 68752841; Fax: þ 86 23 68752262; E-mail: hefengtian06@yahoo.com.cn (FH)
or E-mail: lianjiqin@sina.com (JL)
5These authors contributed equally to this work.
Received 03.9.12; revised 07.1.13; accepted 08.1.13; Edited by T Bruner.
Keywords: ApoG2; ROS; autophagy; HCC
Abbreviations: ApoG2, apogossypolone; ROS, reactive oxygen species; NAC, N-acetyl-cysteine; HCC, hepatocellular carcinoma
Citation: Cell Death and Disease (2013) 4, e489; doi:10.1038/cddis.2013.17
& 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13
www.nature.com/cddis
autophagosome formation. Light chain 3 (LC3)-II is widely
used as a marker of autophagy because its lipidation and
specific recruitment to autophagosomes provide a shift from
diffuse to punctate staining of the protein, and increases its
electrophoretic mobility on gels compared with LC3-I.16
Significant conversion of LC3-I to LC3-II was detected in
HepG2 and Hep3B cells treated for 24 h with 10 mM ApoG2
(Figure 1a, rapamycin was used as positive control).
Autophagy inhibitor chloroquine (CQ) blocks the fusion of
autophagosomes and lysosomes, and results in the accu-
mulation of LC3-II when combined with ApoG2 (Figure 1a).
ApoG2-induced LC3-II conversion in HCC cells was dose-
and time-dependent (Figures 1b and c). Next, we examined
the ApoG2-induced autophagy by LC3–GFP puncta forma-
tion. Recruitment of LC3-II to the autophagosomes is
characterized by a punctate pattern of its subcellular
localization.16 In HepG2 and Hep3B cells transfected with
LC3–GFP, ApoG2-induced autophagy is evident by a
punctate pattern of green-fluorescent LC3–GFP (Figure 1d,
white arrows), whereas the DMSO control cells exhibited
diffuse LC3-associated green fluorescence. Transmission
electron microscopy (TEM) revealed an abundance of
autophagosomes in HCC cells treated with ApoG2
(Figure 1e, black arrows). Collectively, these observations
demonstrate that ApoG2 treatment activates autophagic flux
in HCC cells.
ApoG2 interrupts the interaction of Beclin-1 and
Bcl-2. To investigate the mechanism of autophagy induced
by ApoG2, we used a co-immunoprecipitation (Co-IP)
pull-down assay. Immunoprecipitation of Beclin-1 with
specific antibodies pulled down Bcl-2 from whole-cell
lysates (WCL) (Figure 2a). This indicated that Bcl-2 and
Beclin-1 were bound to each other in the cells, consistent
with previous studies.17,18 Immunoprecipitation of Beclin-1
also pulled down Bcl-xL, but not Mcl-1 (Figure 2a). ApoG2
treatment abolished this Bcl-2–Beclin-1 interaction as
indicated by the disappearance of the specific pull-down
bands (Figure 2a). ApoG2 also abrogated the binding of
Bcl-xL with Beclin-1 (Figure 2a). Furthermore, immunopre-
cipitation of Bcl-2 also pulled down Beclin-1, which can be
interrupted by ApoG2 treatment (Figure 2b). Consistent with
Rubinstein’s study, Mcl-1 also binds with Atg12 directly
(Supplementary Figure S1). However, ApoG2 treatment did
not disrupt or increase the interaction of Atg12 and Mcl-1
(Supplementary Figure S1). This data suggests a multi-
faceted BH3-mimetic capacity for ApoG2. Our data demon-
strates that ApoG2 interrupts the interactions between
Beclin-1 and Bcl-2/Bcl-xL, thus releasing the BH3-only
pro-autophagic protein Beclin-1, which in turn triggers the
autophagic cascade.
To further delineate the role of Beclin-1–Bcl-2 interaction in
ApoG2-induced autophagy, we knocked down Beclin-1
protein levels by siRNA. Beclin-1 knockdown resulted in
significant decrease but not complete disappearance of LC3-II
conversion (Figure 2c) and positive punctuate GFP–LC3 HCC
cell numbers (Figure 2d). These results demonstrate that the
interaction of Bcl-2 and Beclin-1 has a key role in ApoG2-
triggered autophagy, but additional pro-autophagy pathways
are also involved.
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Figure 1 ApoG2 induces autophagy in HCC cells. (a) Cells were treated with 10mM ApoG2, 50 nM rapamycin or ApoG2 combined with 40mM CQ for 24 h. Then total
protein was extracted and western blot was used to detect the expression of LC3. (b,c) Dose response for 24 h (b) and time course at 10mM concertration (c) of ApoG2-
induced autophagy in HCC cells. (d) Cells expressing LC3–GFP were treated with or without 10 mM ApoG2 and processed for fluorescent microscopy 24 h later. White arrows
indicate the characteristic punctate pattern of LC3–GFP, which occurs upon autophagic induction. (e) Representative electron micrograph images showing autophagic
vacuoles (black arrows) following ApoG2 treatment
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ApoG2 promotes ROS generation in HCC cells. As BH3
mimetics can activate multiple pro-autophagic pathways
beside Beclin-1 activation19 and ApoG2 triggers the genera-
tion of cellular ROS in nasopharyngeal carcinoma,20 we next
investigated whether ROS was triggered by ApoG2 in HCC
cells by examining the intracellular levels of GSH, O2
 and
ROS. Consistent with the study on gossypol,21 treatment with
ApoG2 significantly decreased intracellular GSH level
(Figure 3a), and increased O2
 and ROS level (indicated by
increased green fluorescence, Figures 3b–d). Additionally,
this phenotype was attenuated by antioxidant N-acetyl-
cysteine (NAC) co-treatment (Figures 3a–d). These results
indicate that ApoG2 promotes ROS generation in HCC cells.
ApoG2 induces ROS-mediated autophagy in HCC cells.
To examine the role of ROS in ApoG2-induced autophagy,
HCC cells were co-treated with ApoG2 and NAC. As shown
in Figure 4a, co-treatment with NAC decreased ApoG2-
induced LC3 conversion in HCC cells. This data indicates
that ApoG2 induces ROS-mediated autophagy in HCC cells.
Next, we determined whether additional pro-autophagy
pathways are involved in ROS-mediated autophagy upon
ApoG2 treatment. Consistent with the previous report,19
ApoG2 induced the hyperphosphorylation of ERK and JNK,
as well as a reduction in the phosphorylation of mammalian
target of rapamycin (mTOR) (Figure 4b). Co-treatment with
NAC attenuated the effects of ApoG2 on ERK, JNK and
mTOR, suggesting that these pathways are regulated by
ROS levels in HCC cells. As Bim and Atg5 are the targets of
JNK, our data further demonstrated that ApoG2 treatment
upregulated Bim and Atg5 in HCC cells (Supplementary
Figure S2). The effect of ApoG2 on Bim and Atg5 can be
suppressed by NAC co-treatment (Supplementary Figure
S2). Recently, high mobility group box 1 (HMGB1) protein
was discovered to be a critical pro-autophagic protein;
furthermore, ROS promotes cytosolic translocation of
HMGB1 and thereby enhances autophagic flux.22 Consistent
with published data, treatment with ApoG2 increased the
cytosolic HMGB1 level and decreased the nucleic HMGB1
level, which is then attenuated by NAC co-treatment in HCC
cells (Figure 4c). Knockdown of endogenous HMGB1 also
reduced ApoG2-induced autophagy in HCC cells (Figure 4d).
We conclude that multiple pro-autophagic pathways are
involved in ROS-mediated autophagy after ApoG2 treatment
in HCC cells.
Antioxidant NAC enhances ApoG2-induced apoptotic
cell death. To assess whether ROS-mediated autophagy is
responsible for cell death, HCC cells were treated with
ApoG2, NAC or their combination. As shown in Figures 5a
and b, compared to ApoG2 alone, combination treatment
with ApoG2 and NAC dramatically decreased cell viability
and increased total cell death. The effect of ApoG2 and NAC
on cell death was also found in human T-cell lymphoblast-like
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Figure 2 ApoG2 interrupts the interaction of Beclin-1 and Bcl-2. (a,b) Cell lysates were mixed with DMSO or 10 mM ApoG2 for 1 h. Antibodies against Beclin-1 (a) or Bcl-2
(b) were added to immunoprecipitate the Beclin-1- or Bcl-2-containing complexes, and then immunoblotted for Bcl-2, Bcl-xL, Mcl-1 or Beclin-1. (c) Cells were transiently
transfected with either control siRNA or siRNA-specific Beclin-1. Twenty-four hours after transfection, cells were treated with DMSO or ApoG2 for 24 h, then subjected to
immunoblot analysis for Beclin-1 and LC3. (d) Cells expressing LC3–GFP were transfected with either control siRNA or siRNA-specific Beclin-1. Twenty-four hours after
transfection, cells were treated with DMSO or ApoG2 for 24 h, a statistical analysis of the percentage of cells containing five or more GFP–LC3 puncta (50 green-fluorescent
cells in one field, n¼ 5). Data represent the mean value and from three independent experiments. **Po0.01, ***Po0.001
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Jurkat cell, but not in human normal liver L02 cells and
human embryonic kidney 293 cells (Supplementary Figures
S3 and S4). These observations could be due to increased
PARP cleavage (Figure 5c) and apoptotic cells (Figures 5d
and e). As Atg5 is a key regulator of autophagy and
apoptosis, we further investigate the role of Atg5 in ApoG2-
induced cell death. Overexpression of Atg5 in HCC cells
significantly reduced ApoG2-induced cell death and the
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cleavage of caspase-3 (Supplementary Figure S5), whereas
downregulation of Atg5 in HCC cells dramatically enhanced
cell death and caspase-3 cleavage (Supplementary Figure
S5). NAC co-treatment downregulated the effect of Atg5
overexpression on ApoG2-induced cell death, but had no
effect in Atg5 knockdown cells (Supplementary Figure S5).
Our data strongly suggest that suppression of the ROS-
mediated autophagy induction potentiates apoptosis induc-
tion and cell killing by ApoG2.
Discussion
In the present study, we identified for the first time that anti-
apoptotic Bcl-2 protein inhibitor, ApoG2, induced autophagy
through Beclin-1- and ROS-dependent manners. Our working
model (Figure 6) summarizes how ApoG2 induces autophagy
by several means: abrogating the interaction of Beclin-1 and
Bcl-2/xL, promoting ROS generation and therefore stimulating
phosphorylation of ERK and JNK, increasing HMGB1
translocation and suppressing mTOR. Suppression of the
ROS-mediated autophagy by antioxidant NAC potentiates
apoptosis induction and cell killing by ApoG2.
The mechanisms of BH-3 mimetics inducing autophagy
through blocking the interaction of Beclin-1 and Bcl-2/xL are
well documented.16,23 ApoG2, a new derivative of gossypol, in
which the two aldehyde groups of gossypol are completely
removed, interrupts the interaction of Beclin-1 and Bcl-2/xL
but not Mcl-1. The same effect was found in compound
gossypol.24 In spite of Mcl-1’s ability to regulate autophagy
through binding with Beclin-1,25 most of BH-3 mimetics
(except apogossypol derivative BI-97C1)26 are unable to
block it. The reasons may be due to the weak interaction
between Beclin-1 and Mcl-1, and the low affinity of BH-3
mimetics with Mcl-1.27
Besides dissociation of Beclin-1 from its inhibitory factors,
the study by Malik et al.19 showed that BH-3 mimetics also
activate multiple pro-autophagic signal transduction path-
ways. Our data showed that knockdown of Beclin-1 only partly
suppressed ApoG2-induced autophagy, suggesting that there
are additional pathways independent of Beclin-1 to induce
autophagy. Consistently, ApoG2 causes the activations of
ERK, JNK and HMGB1 translocation, and the inhibition of
mTOR. Mammalian target of rapamycin (mTOR) is a
conserved Ser/Thr kinase that inhibits autophagy by activa-
tion of the ATG1 and Akt kinases.28 MEK/ERK pathway
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induces autophagy by several means: abrogating the interaction of Beclin-1 and
Bcl-2/xL, promoting ROS generation and therefore stimulating phosphorylation of
ERK and JNK, increasing HMGB1 translocation and suppressing mTOR
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regulates autophagy in Beclin-1-independent manners.29
Activation of JNK mediates the phosphorylation of Bcl-2,
Atg4 and p53, which contributes to autophagy induction.30,31
HMGB1 regulates autophagy partly through increasing
transcriptional activities of JNK and ERK.32 Taken together,
ApoG2 induces autophagy by Beclin-1-dependent and
-independent manners.
ROS induces non-canonical autophagy by activating ERK
and JNK,33 inhibits mTOR signaling by activating AMP-
activated protein kinase (AMPK)34 and promotes the translo-
cation of oxidative HMGB1 from nucleus to cytoplasma.35
Previous data also reports that ApoG2 stimulates ROS
production.20 Therefore, we presume that ROS production
may be responsible for the activation of multiple pro-autophagic
signal pathways upon ApoG2 treatment. We conclude that
ApoG2 stimulates ROS production by downregulating GSH
level and upregulating O2
 in cells. Similar results were found in
gossypol-treated cells,36 the mechanism may be through
inhibiting electron transport in the mitochondria.37
The induction of ROS in HCC cells following ApoG2
treatment represents an alternative mechanism of ApoG2
cytotoxicity. The primary oxidation product of gossypol is
gossypolone, and has been implicated in the formation of a
redox system leading to additional free radical generation.38
Consistent with published literature,21 our study showed that
ApoG2-induced ROS has a cytoprotective role, which may
depend on ROS-mediated autophagy in HCC cells.
Autophagy, a process of intracellular organelle degrada-
tion, has either pro-survival or pro-death roles in cells when
treated with a variety of chemotherapeutic drugs.39,40
Supported by our current study, targeting autophagy may
become a new therapeutic strategy for overcoming autop-
hagy-mediated chemoresistance.41 NAC is well tolerated by
humans and mice,42,43 and has been shown to block ROS
generation in mouse tumors.44 Dietary supplements with high
levels of NAC during ( )-gossypol treatment may inhibit ROS
generation in tumor cells, prevent oxidation of ( )-gossypol,
and increase its efficacy and specificity against B-cell
lymphoma. We conclude that the co-treatment of NAC with
ApoG2 sensitizes HCC cells to cell death via an inhibition of
cytoprotective authophagy. Furthermore, our study may
provide a new direction on rational design of clinical trials as
well as new strategies to overcome resistance to current
cancer therapy.
Previous publication showed that ApoG2 induces apoptosis
in HCC SMMC-7721 cells by downregulating anti-apoptotic
proteins Bcl-2, Mcl-1 and Bcl-xL, upregulating pro-apoptotic
protein Noxa, and promoting the activities of caspases-9
and -3.10 Cosistent with this report, ApoG2 induced apoptotic
cell death in HepG2 and Hep3B cells. However, ApoG2 has
little effect on human normal liver L02 cells and human
embryonic kidney 293 cells. The reason may be due to the low
expression level of anti-apoptotic protein Bcl-2/xL in these
cells (Supplementary Figure S6). This point needs to be
further validated.
Materials and Methods
Cell culture and reagents. Cell culture reagents and fetal bovine serum
(FBS) were purchased from HyClone (Waltham, MA, USA). Human hepatocellular
cell lines HepG2 and Hep3B were obtained from American Type Culture Collection
and were cultured in DMEM nutrient mixture supplemented with 10% FBS and
antibiotics. ApoG2 was a gift kindly provided by the University of Michigan (Ann
Arbor, MI, USA), and dissolved in DMSO at 20 mM as stock solution. NAC, CQ,
rapamycin and acridine orange were from Sigma-Aldrich (Louis, MO, USA);
Reactive Oxygen Species Assay Kit and Annexin V-FITC Apoptosis Detection Kit
were purchased from Beyotime (Bejing, China). LC3 cDNA was kindly provided by
Dr. N. Mizushima and T. Yoshimori at Osaka University, Japan.
Cell viability assay. CCK8 assay was used to assess cell viability. Cells
were incubated in triplicate in 96-well plates in the presence or absence of ( )-
gossypol for 24 h. Then the plates were centrifuged and the supernatant was
discarded. Subsequently, each well was added with 90 ml RPMI 1640 medium
containing 10% FBS and 10ml CCK8. The plate was incubated for 2 h and
measured using microplate reader at 450 nm.
Trypan blue exclusion assay. The treated cells were adequately
suspended and 0.4% (w/v) trypan blue solution was added at a volume ratio
(the cell suspension to the trypan blue solution) of 9:1. Subsequently, the cells
were counted under an optical microscope. Cells failing to exclude the dye were
defined as dead cells. The total death rate (%)¼ numbers of dead cells/(numbers
of living cellsþ numbers of dead cells) 100.
Western blot. Preparation of whole-cell protein lysates and western blot
analysis were performed as described previously.45 Antibodies against
microtubule-associated protein-1 LC3, PARP, HMGB1, JNK, ERK, mTOR, Lamin
B1, Bcl-xL were purchased from Cell Signaling (Boston, MA, USA) and the
antibodies against Bcl-2, Mcl-1 and Beclin-1 were from Santa Cruz (Santa Cruz,
CA, USA).
ROS generation detection. The intracellular ROS levels were measured
by detecting the conversion of cell permeable 2, 7-dichlorofluorescein diacetate
(DCFH-DA) to fluorescent dichlorofluorescein (DCF). Cells were seeded in 12-well
plates and treated with the agents indicated for 12 h. After washed with PBS for
three times, cells were incubated with DCFH-DA at 37 1C for 25 min. Then the
DCF fluorescence distribution was detected by fluorescence microplate reader at
an excitation wavelength (488 nm) and emission wavelength (525 nm).
GFP-LC3 analysis. Cells were transfected with GFP–LC3 vector using
Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA). Twenty-four
hours later, cells were treated with drugs for 24 h, then fixed in 4% formaldehyde for
10 min. Cells were then washed three times with PBS and observed under a
fluorescence microscope (OLYMPUS IX81, Tokyo, Japan) with  40 lens.
TEM. Preparation of the ultrathin sections were described previously.24 Ultrathin
sections (65 nm) were examined using a TECNAI-10 TEM.
Co-immunoprecipitation experiments. HepG2 cells (5 106) were
plated on 15 cm dishes and allowed to attach overnight. After treatment with either
DMSO or 10mM ApoG2 for 6 h at 37 1C, the whole-cell lysate was generated by
collecting the supernatant at a low speed spin (1000 g) to pellet nuclei after
hypotonic lysis. WCL was precleared with protein A-agarose, then mixed with
antibodies of Beclin-1 or Bcl-2 for 1 h at 4 1C (each IP reaction consisted of 1 mg
total protein). The immunoprecipitates were captured on protein A-agarose and
analyzed by immunoblotting with antibodies against Beclin-1, Bcl-2, Bcl-xL or
Mcl-1, respectively.
Small interfering RNA transfection. siRNAs to Beclin-1, Hmgb1 or
control siRNA were obtained from Dharmacon (Lafayette, CO, USA). Cells were
plated in 6-well plates and transfected with siRNA (100 pmol per well) by
Lipofectamine 2000 according to the manufacturer’s manual. ApoG2 was added to
the cells 36 h after transfection. For western blot, cells were collected after an
additional 24 h culture.
Detection of apoptosis. Apoptosis was evaluated by Annexin V-FITC
apoptosis detection kit following the manufacturer’s instructions. Briefly, treated
cells were harvested and incubated with AnnexinV-FITC and propidiumiodide (PI)
at room temperature, respectively, for 10 min.46 Subsequently, samples were
analyzed by a FACScan flow cytometer. Hochest33258 staining was performed
according to the manufacturer’s instruction.
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Statistic analysis. The data were represented as the mean±S.D. from
triplicate experiments. Two-way ANOVA was used to analyze the variance of
different groups. A threshold of Po0.05 was defined as statistically significant.
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